今日（2.26），港股创新药板块回调，创新药纯度100%的港股通创新药ETF(159570)跌超1.5%，盘中成交额突破6亿元，资金逆市净流入超 1400万元！资金面上，近10日累计"吸金"超3.6亿元！最新规模超250亿元，同类规模遥遥领先！ 短期来看，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时预计2026年更多创新药企业有望扭亏并大幅释 放利润。展望全年，AACR（4月）、ASCO（5月）、ESMO（10月）等学术会议上国产创新药有望进一步带来临床数据的兑现。整体上， 创新药前期回调较为充分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。（来源：国金证券20260207《业绩与临床数据催 化密集，看好创新药板块回暖》） 【机构盘点：2026年创新药投资三大主线】 国金证券指出，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。 据医保魔方统计，2025年中国新药License-out交易数量达158笔，总交易规模达1357亿美元，总首付款规模达70亿美元，交易数量与金额均 创近十年新高。出海BD的繁荣，一方面有 ...

Group 1 - The Hong Kong innovative drug sector experienced a downward trend, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping over 1% in early trading on February 26 [1] - Among the constituent stocks, Jiage Ankang-B led with a gain of over 5%, while Baiji Shenzhou fell sharply by 3% [1] - The industry is seeing active external licensing transactions, with Innovent Biologics and Eli Lilly forming a global strategic partnership focused on oncology and immunology [3] Group 2 - Key pipelines are making progress overseas, with two innovative drugs from CSPC Pharmaceutical Group starting Phase III clinical trials and receiving FDA IND approval [3] - Jianghai Securities predicts that by 2026, pharmaceutical business development (BD) transactions will focus on unmet clinical needs, technological differentiation, and globalization [3] - Huachuang Securities emphasizes the transition in the innovative drug industry from quantity to quality, suggesting a focus on differentiated domestic and international pipelines by 2025 [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, with top ten weighted stocks including CSPC Pharmaceutical Group and Baiji Shenzhou [3]

付款总额最高达4.95亿美元 根据双方签订的合作协议，辉瑞将获得埃诺格鲁肽在中国大陆的独家商业化权益，同时先为达生物为许 可产品的药品上市许可持有人，负责许可产品的研发、注册、生产及供应。合作框架下，先为达生物将 有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。 作为先为达生物的核心产品，埃诺格鲁肽是一款具有cAMP偏向性的新型长效GLP-1受体激动剂。偏向 型激动剂的核心优势在于可在不触发过度受体内吞的情况下，保留下游治疗效果（包括胰岛素分泌和食 欲抑制），从而在降糖和减重方面极大增强疗效。 2026年1月底，埃诺格鲁肽在国内获批上市，用于成人2型糖尿病患者的血糖控制，成为全球首个获批上 市的cAMP偏向型GLP-1受体激动剂。此外，其成人长期体重管理适应症的上市许可申请已获国家药监 局受理。 值得注意的是，埃诺格鲁肽是先为达生物第一款获批上市的产品，该公司其余管线产品大多仍处于早期 临床阶段，距离商业化落地尚有一段距离。受此影响，叠加创新药研发的高投入特性，先为达生物长期 处于亏损状态。 财务数据显示，2023年、2024年及2025年上半年，先为达生物研发开支分别为 ...

本报记者 曹卫新 2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方NextPharma数据库显示，截至2月25 日，年内中国创新药已发生44起对外授权（license-out）交易事件，首付款约为31.23亿美元，总金额达532.76亿美元。 普华永道中国医药医疗行业主管合伙人徐佳博士在接受《证券日报》记者采访时表示："近期中国创新药海外授权 （License-out）交易密集落地，折射出中国创新药产业正从'跟跑'向'并跑'乃至'领跑'转变，实现了从'引进模仿'向'创新输出'的 结构性跨越。这不仅标志着中国正成为全球不可或缺的创新策源地，也意味着中国在全球医药创新价值链中的话语权和影响力 持续增强。" 跨境BD交易密集落地 医药魔方NextPharma数据库显示，2025年，中国创新药BD"出海"授权全年交易总金额达到1356.55亿美元，首付款70亿美 元，交易总数量达到157起，各个维度的数据统计均创历史新高。 进入2026年，中国创新药对外BD交易势头不减。1月16日，西比曼生物科技（一家处于临床阶段的专注于创新细胞疗法发 现和开发的全球性生物制药公司）宣布与阿斯利康达成协 ...

千亿注射剂市场风云再起！2025年前三季度，全终端医院注射剂销售额虽同比微降，但生物药强势崛起、独家品种爆发式增长，TOP50榜单迎来大洗牌。13 款新品跻身榜单，1款独家注射剂同比劲增92.26%，齐鲁制药领衔本土药企，与外资分庭抗礼。 4500亿注射剂市场，生物药占居主导 据摩熵医药数据库(https://vip.pharnexcloud.com/?zmt-mhwz)显示，2025年Q1-Q3全终端医院市场（化药+生物药+中成药）中，注射剂销售额突破 4500亿元， 同比下滑 9.76%。品类结构中，生物药 图源：摩熵医药-全终端医院销售数据库 回顾近年走势：2018-2023年注射剂销售额在6691.73亿~7557.34亿元间波动，2020年因多重因素探底至6691.73亿元，2023年回升至7043.94亿元；2024年受宏 观与政策影响回落至6482亿元，降幅约7.98%。进入2025年，前三季度同比再降9.76%，显示行业进入阶段性调整。 治疗领域三强：血液和造血系统药物（22.75%）、抗肿瘤及免疫调节药（22.27%）、系统用抗感染药（14.6%）稳居前三，合计占据近六成份额。 图源：摩熵医 ...

Core Viewpoint - Xianweida Biotech has established a commercialization partnership with Pfizer China for its first approved product, Enoglutide, with a total payment of up to $495 million, marking a significant step in its strategy to penetrate the competitive GLP-1 market [1][2]. Group 1: Partnership Details - The agreement grants Pfizer exclusive commercialization rights for Enoglutide in mainland China, while Xianweida remains the marketing authorization holder responsible for R&D, registration, production, and supply [2]. - The total payment from Pfizer includes an upfront payment and milestone payments related to registration and sales [2]. Group 2: Product Information - Enoglutide is a novel long-acting GLP-1 receptor agonist with cAMP bias, enhancing efficacy in blood sugar control and weight management without triggering excessive receptor internalization [2]. - It was approved for use in adults with type 2 diabetes for blood sugar control in January 2026, becoming the first cAMP biased GLP-1 receptor agonist globally [2]. Group 3: Financial Overview - Xianweida's R&D expenditures for 2023, 2024, and the first half of 2025 are projected to be 456 million, 284 million, and 65 million yuan respectively, totaling over 800 million yuan, while revenues during the same period are expected to be 0, 0, and 91 million yuan, with losses of 620 million, 486 million, and 108 million yuan [3]. Group 4: Market Context - The global weight management drug market is projected to grow from $112.8 billion in 2024 to $165.9 billion by 2029, indicating a high-growth opportunity for Xianweida [6]. - The competitive landscape includes established players like Novo Nordisk and Eli Lilly, as well as local competitors such as Innovent Biologics, intensifying the market rivalry [6]. Group 5: Strategic Moves - Xianweida has initiated a global strategy, having submitted its IPO application to the Hong Kong Stock Exchange in September last year, aiming to become the "first stock in weight management" [5]. - The company has also signed agreements for future development and commercialization of Enoglutide in South Korea and other regions, indicating proactive steps to enhance its market presence [6].

Group 1: Market Performance - The A-share biopharmaceutical ETF Huatai Fuhua (159839) rose by 1.1%, with a total trading volume exceeding 22 million yuan, marking the fourth consecutive day of inflows totaling over 20 million yuan [2] - The Hong Kong biopharmaceutical ETF Huatai Fuhua (513280) fluctuated and closed flat, with a trading volume exceeding 42 million yuan, and a net inflow of over 17 million yuan in the last 60 days [3] - The majority of the popular component stocks in the biopharmaceutical ETF Huatai Fuhua (159839) showed positive performance, with Changchun High-tech hitting the daily limit and its subsidiary GenSci141 ointment receiving clinical trial approval [5] Group 2: Company Performance - WuXi AppTec (药明康德) reported a significant performance increase, with a projected net profit growth of 41.3% in 2025, driven by the TIDES business, which saw revenue growth exceeding 90% [8] - WuXi Biologics (药明生物) achieved a record total of 945 projects, with a 30% growth in dual monoclonal antibodies and ADC projects, indicating strong future revenue potential [8] - The domestic clinical CRO market is expected to return to a growth trajectory in 2025, benefiting companies like Tigermed (泰格医药) from improved order prices and increased clinical pipeline numbers [8] Group 3: Industry Trends - The global CXO industry is expected to continue its strong recovery, with significant investment and transaction demand in the biotech and pharmaceutical sectors anticipated to rebound in 2025 [7] - The Chinese innovative drug market is showing robust activity, with a 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic market [7] - The Chinese innovative drug sector is transitioning from pipeline expectations to revenue realization, with over 70% of companies projected to achieve positive revenue growth in 2025 [11]

Investment Rating - The industry investment rating is maintained at "Overweight" [7] Core Insights - The report highlights the continuous upgrading of policies in the Heilongjiang biomanufacturing industry, focusing on innovative traditional Chinese medicine and innovative medical devices [4] - The report emphasizes the significant revisions to the Drug Administration Law, which provides institutional support for pharmaceutical innovation and high-quality development [4] - The report identifies three major transformations in China's innovative drug business development (BD) in 2026: technology output combined with product authorization, platform cooperation, and global parallel innovation [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -7.06% compared to the CSI 300 index, with an absolute return of 11.53% [3] Investment Highlights - The report notes that BD transactions in the pharmaceutical sector are focused on unmet clinical needs, technological differentiation, and global value [6] - Key areas of focus include oncology therapies such as dual antibodies, ADCs, and TCE combinations, with significant financial agreements highlighted, such as a $650 million upfront payment for a PD-1/VEGF dual antibody [6] - The metabolic disease sector is centered on long-acting GLP-1 and small nucleic acid precision therapies, with notable collaborations resulting in substantial upfront payments and potential total amounts [6] Company-Specific Developments - Companies like Andover Pharmaceuticals and Frontier Biotech have secured significant collaborations with major pharmaceutical firms, indicating a trend towards platform-based cooperation and technology output [7] - Specific collaborations include a $1.05 billion deal for a CTLA-4 inhibitor and a $400 million agreement for small nucleic acid drugs, showcasing the growing interest in innovative therapies [7] - The report suggests monitoring companies such as Rebio Biotech and WuXi AppTec for their advancements in small nucleic acids and platform capabilities [8]

Group 1 - The Hong Kong stock market's innovative drug sector is performing well, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising by 0.56% and achieving a trading volume exceeding 700 million CNY [1] - Over the past 10 days, the ETF has attracted over 360 million CNY in capital, with its latest scale surpassing 25 billion CNY, leading its peers significantly [1] - Key stocks within the ETF, such as Federated Pharmaceutical and Rongchang Biopharmaceutical, have shown notable gains, with Federated Pharmaceutical increasing by over 6% [1][2] Group 2 - The innovative drug business development (BD) is focused on unmet clinical needs, technological differentiation, and global value, with significant transactions in oncology and metabolic disease sectors [3][4] - In oncology, notable advancements include Rongchang Biopharmaceutical's PD-1/VEGF dual antibody RC148, which received a substantial upfront payment of 650 million USD from a partnership with Aibowei [3] - The metabolic disease sector is highlighted by Shiyao Group's GLP-1 receptor agonist SYH2082, which secured a 1.2 billion USD upfront payment from AstraZeneca [3] Group 3 - The mRNA vaccine sector is experiencing rapid approvals, with several domestic products receiving IND approvals, indicating a swift advancement in local innovation [5] - The FDA has relaxed its drug review policies, allowing for a single key clinical trial to suffice for new drug approvals, which is expected to significantly reduce development timelines and costs [6] - New drug approvals include Hansoh Pharmaceutical's lung cancer drug "Amatinib," which has been granted marketing authorization in the EU for specific NSCLC patient populations [6]

交易流向 午间指数表现 ：下跌 1.9% ：下跌 2.1% ：下跌 2.4% ：1390 亿港元 ：1.56 亿美元 领涨板块：必需消费品（-0.0%）、电信（-0.1%）、工业（-0.2%） 领跌板块：非必需消费品（-2.5%）、信息技术（-2.8%）、医疗保健（-3.6%） 午间市场点评 香港市场在昨日强势后出现技术性回调，医疗保 午间指数表现 ：下跌 1.9% ：下跌 2.1% ：下跌 2.4% ：1390 亿港元 ：1.56 亿美元 领涨板块：必需消费品（-0.0%）、电信（-0.1%）、工业（-0.2%） 领跌板块：非必需消费品（-2.5%）、信息技术（-2.8%）、医疗保健（-3.6%） 午间市场点评 香港市场在昨日强势后出现技术性回调，医疗保健板块成为主要拖累因素。 A 股节后首个交易日表现强劲，沪深 300 指数上涨 1.33%。 南向投资者在香港市场净卖出，占港股成交额的 22%（高于通常的 20% 以下水平），资金似乎流向 A 股市 场。 Citrini报告对恒生科技指数造成压力，该指数早盘下跌 2.4%。 下跌 4.6%，反映出 AI 板块情绪疲软。 今日市场催化剂有限，但我们的主要做空 ...